The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...
A recent Federal Trade Commission report highlights a concerning trend in the pharmaceutical industry, where pharmacy benefit ...
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from ‘excess’ ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...